Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 91
- Registration Number
- NCT01608087
- Locations
- π³πΏ
1302.1.002 Boehringer Ingelheim Investigational Site, Auckland NZ, New Zealand
π³πΏ1302.1.001 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT01605461
- Locations
- πΊπΈ
1241.22.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01595854
- Locations
- π©πͺ
1160.141.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT01594515
- Locations
- π©πͺ
1305.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01594125
- Locations
- π―π΅
1199.120.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan
π―π΅1199.120.005 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan
π―π΅1199.120.003 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL
- Conditions
- Healthy
- Interventions
- Drug: BI 187004 CLDrug: Placebo to BI 187004 CL
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01587417
- Locations
- π©πͺ
1307.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX
- Conditions
- Healthy
- Interventions
- Drug: Placebo to BI 163538 XXDrug: BI 163538 XX
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01587391
- Locations
- π©πͺ
1291.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Safety Tolerability and Pharmacokinetic of BI 411034
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT01581684
- Locations
- π©πͺ
1308.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01581658
- Locations
- π―π΅
1245.53.001 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka, Japan
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01581931
- Locations
- π©πͺ
1288.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany